Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kaletra Induction-Maintenance Strategy in HIV/HCV Co-infected Subjects
NCT00121017Phase 2Withdrawn
- Sponsor
- Abbott Laboratories
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of lopinavir + ritonavir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Proportion of subjects with plasma HIV-1 RNA < 50 copies/mL at Week 96. Status: withdrawn.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00121017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121017.